Not finding it? Sign in to also search OpenAlex live.
-
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Ulrike Anneliese Nitz, Oleg Gluz, Monika Graeser, Matthias Christgen, Sherko Küemmel, Eva‐Maria Grischke, +43 more
93citations -
Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT+ study2023 Journal of the Neurological Sciences article Medicine Myasthenia Gravis and Thymoma Open access
Vera Bril, Mamatha Pasnoor, Chafic Karam, Stojan Perić, Jan De Bleecker, Hiroyuki Murai, +11 more
0citations -
Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)
Andreas Meisel, Carlo Giuseppe Antozzi, Ratna Bhavaraju-Sanka, Jan De Bleecker, Wan-Yi Huang, Rosa H. Jimenez, +10 more
0citations -
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
Nadia Harbeck, Oleg Gluz, Matthias Christgen, Monika Graeser, Felix Hilpert, Katja Krauss, +11 more
18citations -
Approaches to improve and adapt maternal mortality estimations in low‐ and middle‐income countries: A scoping review2023 International Journal of Gynecology & Obstetrics article Medicine Global Maternal and Child Health Open access
Maya Tholandi, Siem Zethof, Young Mi Kim, Abera Kenay Tura, Johannes C. F. Ket, Merlin Luke Willcox, +2 more
5citations -
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta López‐Yurda, Valesca P. Retèl, Marthe S. Paats, +16 more
12citations -
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Rachel Würstlein, Sherko Kümmel, +15 more
12citations -
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial2021 The Lancet Neurology article Medicine Myasthenia Gravis and Thymoma Open access cited by 7 patents
James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Perić, Temur Margania, +89 more
733citations -
Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results2021 Journal of the Neurological Sciences article Medicine Myasthenia Gravis and Thymoma cited by 1 patent
Renato Mantegazza, Vera Bril, Tuan Vu, Chafic Karam, Stojan Perić, Temur Margania, +10 more
1citations -
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Ulrike Anneliese Nitz, Oleg Gluz, Mathias Christgen, E.‐M. Grischke, Doris Augustin, Sherko Küemmel, +14 more
1citations -
Allopregnanolone Is Associated with a Stress-Induced Reduction of Heart Rate Variability in Premenstrual Dysphoric Disorder2023 Journal of Clinical Medicine article Medicine Heart Rate Variability and Autonomic Control Open access
Ajna Hamidovic, John M. Davis, Fatimata Soumare, Aamina Naveed, Yaseen Ghani, Selma Semiz, +2 more
22citations